Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology

 Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology

Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for Gene Therapy Manufacturing Technology

Shots:

  • Ultragenyx to receive $200m up front including $125M in cash & $75M equity investment at $60/share, $25M on completion of technology transfer the HeLa PCL and HEK293 platforms along with royalties on sales of products manufactured in either system
  • Ultragenyx get a non-exclusive license to IP, including know-how and patent applications, regarding its manufacturing technology platforms for AAV-based gene therapy products
  • Ultragenyx retains the exclusive right to utilize its manufacturing technology for its current target indications and additional indications identified in the future

Click here ­to­ read full press release/ article | Ref: Ultragenyx | Image: Ultragenyx

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post